Radiation-Induced Toxicity Risks in Photon Versus Proton Therapy for Synchronous Bilateral Breast Cancer

Stick, Line Bjerregaard; Jensen, Maria Fuglsang; Bentzen, Soren M.; Kamby, Claus; Lundgaard, Anni Young; Maraldo, Maja Vestmo; Offersen, Birgitte Vrou; Yu, Jen; Vogelius, Ivan Richter

Published in:
International Journal of Particle Therapy

DOI:
10.14338/IJPT-21-00023.1

Publication date:
2022

Document version
Publisher's PDF, also known as Version of record

Document license:
CC BY

Citation for published version (APA):
Stick, L. B., Jensen, M. F., Bentzen, S. M., Kamby, C., Lundgaard, A. Y., Maraldo, M. V., Offersen, B. V., Yu, J., & Vogelius, I. R. (2022). Radiation-Induced Toxicity Risks in Photon Versus Proton Therapy for Synchronous Bilateral Breast Cancer. International Journal of Particle Therapy, 8(4), 1-13. https://doi.org/10.14338/IJPT-21-00023.1
Radiation-Induced Toxicity Risks in Photon Versus Proton Therapy for Synchronous Bilateral Breast Cancer

Line Bjerregaard Stick, PhD1,2,3; Maria Fuglsang Jensen, PhD3; Søren M. Bentzen, PhD, DMSc4; Claus Kamby, MD, PhD1; Anni Young Lundgaard, MD1; Maja Vestmo Maraldo, MD, PhD1; Birgitte Vrou Offersen, MD, PhD3,5; Jen Yu, PhD6; Ivan Richter Vogelius, PhD, DMSc1,7

1Department of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
2Niels Bohr Institute, Faculty of Science, University of Copenhagen, Copenhagen, Denmark
3Danish Center for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark
4Greenebaum Comprehensive Cancer Center and Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD, USA
5Department of Experimental Clinical Oncology & Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
6Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA
7Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Abstract

Purpose: This study compares photon and proton therapy plans for patients with synchronous bilateral early breast cancer and estimates risks of early and late radiation-induced toxicities.

Materials and Methods: Twenty-four patients with synchronous bilateral early breast cancer receiving adjuvant radiation therapy using photons, 3-dimensional conformal radiation therapy or volumetric modulated arc therapy, were included and competing pencil beam scanning proton therapy plans were created. Risks of dermatitis, pneumonitis, acute esophageal toxicity, lung and breast fibrosis, hypothyroidism, secondary lung and esophageal cancer and coronary artery events were estimated using published dose-response relationships and normal tissue complication probability (NTCP) models.

Results: The primary clinical target volume V95% and/or nodal clinical target volume V90% were less than 95% in 17 photon therapy plans and none of the proton plans. Median NTCP of radiation dermatitis grade 2 was 18.3% (range, 5.4-41.7) with photon therapy and 58.4% (range, 31.4-69.7) with proton therapy. Median excess absolute risk (EAR) of secondary lung cancer at age 80 for current and former smokers was 4.8% (range, 0.0-17.0) using photons and 2.7% (range, 0.0-13.6) using protons. Median EAR of coronary event at age 80, assuming all patients have preexisting cardiac risk factors, was 1.0% (range, 0.0-5.6) with photons and 0.2% (range, 0.0-1.3) with protons.

Conclusion: Proton therapy plans improved target coverage and reduced risk of coronary artery event and secondary lung cancer while increasing the risk of radiation dermatitis.

Keywords: proton therapy; bilateral breast cancer; treatment planning; bioeffect modeling; normal tissue complication probability
Introduction

Adjuvant breast cancer radiation therapy lowers the risk of recurrence and improves survival in selected patients [1, 2]; however, it comes with a spectrum of side effects ranging from relatively mild and transient to progressive and potentially fatal conditions. Most breast cancer patients treated with radiation therapy using state-of-the-art photon therapy receive adequate target coverage with low exposure of normal tissue [3]. However, a subset of patients may benefit from favorable dose distributions that can be achieved with spot-scanning proton therapy [3–7], particularly patients with synchronous bilateral breast cancer [8, 9].

Synchronous bilateral early breast cancers are estimated to account for 1%-3% of all breast cancer incidences [10–12]. Radiation therapy planning for synchronous bilateral breast cancer is challenging, particularly in bilateral high-risk breast cancer with an indication for internal mammary node (IMN) irradiation on both sides. In 3-dimensional (3D) conformal radiotherapy (CRT), medial target coverage may be compromised to avoid tangential field overlap. Volumetric modulated arc therapy (VMAT) can improve target coverage but may result in increased exposure of heart and lungs [13] owing to a sometimes substantial low-dose bath. Comprehensive assessment of a wide range of potential adverse effects of radiation is required to provide a better picture of advantages and disadvantages of competing treatment strategies.

The aim of this study is to compare dosimetric differences in photon and proton therapy plans and estimate risks of a wide range of radiation-induced toxicity in a series of consecutive patients with bilateral breast cancer.

Materials and Methods

Thirty-five consecutive patients with synchronous bilateral early breast cancer received photon radiation therapy at Department of Oncology, Rigshospitalet, between 2013 and 2016. Eleven patients with implants, treated with partial breast irradiation or extended clinical target volume (CTV) modifications were excluded from the study resulting in 24 included patients. The study was approved by the Danish Patient Safety Authority.

A bolus of 5 mm thickness was applied along the mastectomy scar on chest wall targets according to the guidelines of the Danish Breast Cancer Group (DBCG). The patients were CT scanned and treated in the supine position with arms above the head in either free breathing (patients receiving breast only irradiation) or using the noninvasive voluntary deep inspiration breath-hold (DIBH) technique (patients receiving lymph node irradiation) according to institutional guidelines [14]. The same CT scan was used for both the clinically delivered photon therapy plan and the comparative proton therapy plan. If patients were replanned during the course, the plan used for most fractions was selected for the treatment plan comparison.

CTVs were contoured according to DBCG guidelines [15] for patients receiving radiation therapy before 2016 and according to the European Society for Radiotherapy and Oncology (ESTRO) consensus guidelines for patients treated in 2016 [16]. Lymph nodes were for some cases irradiated and included lymph node levels II to IV, interpectoral nodes, and IMN. For some patients who had mastectomies, the primary CTV (CTVp) did include parts of the bolus. For this study, CTVp was cropped 5 mm from the body outline. Also, the heart was contoured or recontoured retrospectively following the contouring atlas by Feng et al [17]. The thyroid gland and esophagus (from the 6th cervical vertebrae to the gastro-esophageal junction) were contoured retrospectively in patients receiving local regional irradiation.

The delivered fractionation scheme was either 40 Gy in 15 fractions (2.67 Gy per fraction) or 50 Gy in 25 fractions (2 Gy per fraction), and it was not necessarily the same for right- and left-sided targets within the same patient. The fractionation scheme was decided according to the guidelines of DBCG and multidisciplinary team discussions. Three patients received unilateral sequential boost of 10 Gy in 5 fractions (1 patient) or 16 Gy in 8 fractions (2 patients), but the boosts were not considered for the purpose of this study.

Clinical planning objectives for patients treated before 2016 were to cover CTVp (whole breast or the chest wall) with 95% to 107% and lymph node CTVs with 90% to 107% of the prescribed dose. Clinical planning objectives for patients receiving radiation therapy in 2016 were V95% (volume that received at least 95% of the prescribed dose) ≥ 98% for CTVp, V90% ≥ 98% for lymph node CTVs, and V107% ≤ 2% for all CTVs. All comparative proton plans were created following the 2016 planning objectives. Dose to normal tissues should be as low as reasonably achievable with specific dose objectives for the heart and lungs (heart: V20Gy/V17Gy ≤ 10% (50Gy in 25 fractions / 40Gy in 15 fractions) and V40Gy/V35Gy ≤ 5% for local regional irradiation and V17Gy ≤ 5% and V35Gy ≤ 1% for breast only irradiation; each lung: V20Gy/V17Gy ≤ 35% and mean dose ≤ 18Gy/16Gy for local regional irradiation and V17Gy ≤ 25% and mean dose ≤ 16 Gy for breast only irradiation.

Challenging cases were discussed in the clinic, and for some patients the dose objectives were compromised.
Photon Therapy Planning

The clinically delivered photon therapy plans were created using the 3D CRT or VMAT technique (see Figure 1). Three-dimensional CRT for patients with no lymph node targets consisted of opposing tangential fields using 2 isocenters centrally placed in the left and right breasts. For patients receiving local regional irradiation, periclavicular fields were added with a field junction at the isocenter. Fields used 6 MV photons as well as field-in-field techniques with supplementary 18 MV fields to ensure homogeneous target coverage. Planning target volumes were not used with 3D CRT, instead the multileaf collimator was adapted to the CTV with a margin of 1 cm for each field. The multileaf collimators were subsequently modified in some patients to shield the heart.

VMAT plans were created with a single isocenter posterior to the sternum and comprised 2 to 3 partial arcs ranging between 220° and 140°. Planning target volumes were generated with a 5 to 7 mm margin to the CTV and afterwards contracted to 3 to 5 mm under the skin surface. The photon therapy plans were generated in the Eclipse treatment planning system (Varian Medical Systems, Palo Alto, California) and calculated using the analytical anisotropic algorithm or the AcurosXB algorithm. For this study, all photon therapy plans were recalculated with the AcurosXB algorithm.

Proton Therapy Planning

The pencil beam scanning proton therapy plans were created in the Eclipse treatment planning system using multifield optimization (see Figure 1). Relative biological effectiveness (RBE) was assumed to be 1.1. Two isocenters were used; 1 centrally aligned with the right-sided CTVs and 1 centrally aligned with the left-sided CTVs. Four to 6 en face fields were used with 2 to 3 per isocenter. Field angles for right-sided targets ranged from 310° to 10° and field angles for left-sided targets ranged from 350° to 50°. Medial hot spots in patients receiving local regional irradiation could be reduced using anterior-posterior field directions (350°-10°) for some of the fields. A range shifter of water-equivalent thickness of 57 mm was applied to cover the superficial target areas. The distance between isocenter and snout position was set to 25 cm. Spots were placed in a hexagonal grid with spot spacing of 0.350 to 0.425 times the full width at half maximum of the spot in air at the given energy. Bolus and superficial clips and wires were delineated, and the density of these structures was assigned to be air by overriding the Hounsfield units.

Abbreviations: CRT, conformal radiotherapy; CTVp, primary clinical target volume (whole breast or chest wall); DVH, dose-volume histogram; IMN, internal mammary nodes; RBE, relative biological effectiveness; VMAT, volumetric arc therapy.

Figure 1. Examples of dose distributions for the clinically delivered photon therapy plan and the comparative proton therapy plan for 2 patients treated with 50 Gy in 25 fractions. The color wash shows 10% to 110% of the prescribed dose. For patient A, adequate coverage of CTVp and IMN was achieved with VMAT but resulted in high exposure of the heart. For patient B (treated with 3D CRT), coverage of CTVp and IMN was compromised (white arrow) to avoid overlapping fields. Adequate target coverage and low exposure of the heart were achievable with protons for both patients.

Stick et al (2021), Int J Particle Ther
The CTVs and heart objectives were optimized robustly using 14 plan uncertainty parameters: ±0.5 cm isocenter shift in x, y, and z direction ±3.5% range uncertainty (12 scenarios) and ±3.5% range uncertainty (2 scenarios). Field uncertainty parameters of ±0.5 cm in lateral direction were applied to account for uncertainty of right- and left-sided fields overlapping when using 2 isocenters. Optimisation structures were created by expanding the CTVs with a 5 mm margin to help increase the dose at the border of the CTV to achieve robust target coverage. The plans were optimized with the nonlinear universal proton optimizer (NUPO) algorithm, and dose calculations were carried out using the proton convolution superposition algorithm with a 0.25-cm dose grid. The plans were normalized such that mean dose to the combined CTVs equaled prescription dose.

The plan creation process had additional steps if different fractionation schemes were used for the right- and left-sided targets: the plan was created and optimized as previously described using 50 GyRBE in 25 fractions; the plan was then copied, and right-sided fields were deleted in one of the plans and left-sided fields were deleted in the other plan. The fractionation scheme was then changed to 40 GyRBE in 15 fractions for the relevant laterality, and the 2 plans were afterwards summed. When reducing dose per fraction, spots may be deleted owing to a minimum allowed spot weight, and thus it was important to go from a 2-GyRBE dose per fraction to 2.67 GyRBE.

**Plan Evaluation**

Homogeneity index (HI) was calculated for the CTVp and defined [18] as:

\[
HI = \frac{D_{2\%} - D_{98\%}}{D_{50\%}}
\]

D2%, D50%, and D98% represent the dose received by 2%, 50%, and 98% of the CTVp, respectively.

Plan uncertainty evaluation against uncertainty in patient positioning in ± x, y, and z (0.5 cm) ± proton beam range (3.5%) were estimated using integrated evaluation tool in Eclipse for all proton plans (14 scenarios). The objective for the plan uncertainty was that at least 13 out of 14 scenarios should fulfil V95% ≥ 95% for CTVp and V90% ≥ 95% for the individual lymph nodes.

Paired, 2-tailed Wilcoxon signed rank test was used to compare dose metrics and estimated risks in the photon versus proton therapy plans.

**Bioeffect Modeling**

We aimed to provide a comprehensive assessment of the risk of toxicity and second malignancy induction following the competing treatment plans. See Table 1 for a summary of the bioeffect modeling studies underlying the applied models and Supplemental Appendix A for a detailed description of the models. We prioritized models based on breast cancer; however, in some cases such data were not available, and we reverted to using data based on non–small cell lung cancer.

The toxicities were grouped in 3 overall categories (a-c):

(a) Early toxicities
   - Radiation dermatitis grade ≥ 2 [19]
   - Radiation pneumonitis grade ≥ 1 [21]
   - Acute esophageal toxicity grade ≥ 2 [22]
(b) Late, non–life-threatening toxicities:
   - Lung fibrosis grade ≥ 2 [24]
   - Breast fibrosis grade ≥ moderate [25]
   - Hypothyroidism [26]
(c) Late, life-threatening toxicities:
   - Coronary artery event at age 80 [27]
   - Secondary lung cancer at age 80 (for current or former smokers) [28]
   - Secondary esophageal cancer at age 80 [29]

For patients treated with 2 fractionation schemes, the 40 Gy in 15 fractions were converted to 50 Gy in 25 fractions for the purpose of modeling risks. For patients treated in 15 fractions, the dose metric used in the models for radiation pneumonitis and coronary artery events were converted to the corresponding biological equivalent dose metric in 25 fractions (Equation A2 in Supplemental Appendix A). Relevant α/β ratios are provided in Table 1. Acute esophageal toxicity, hypothyroidism, and secondary esophageal cancers were only modeled for patients receiving local regional irradiation.
Late, life-threatening toxicities were modeled as excess absolute risk (EAR) of having an event before the age of 80 years. Secondary lung and esophageal cancers were modeled following the methodology in Brodin et al [34]. The EAR of secondary lung cancer for never-smokers was assumed to be 0% since Grantzau et al [28] found a non–statistically significant excess relative risk of 0.06 per Gy to the center of the lung tumor for never-smokers.

Coronary artery events were defined as myocardial infarction, coronary revascularization, death from ischemic or unstable angina [27]. The EAR of a coronary artery event was modeled twice for each patient: first assuming no preexisting cardiac risk factors and second assuming preexisting cardiac risk factors. Cardiac risk factors included current smoking, body mass index ≥ 30, and a history of ischemic heart disease, diabetes, or chronic obstructive pulmonary disease [27].

### Results

Median patient age was 65 years (range, 33-81). Patient and treatment characteristics are provided in Table 2.

The CTVp V95% was less than 95% in 12 photon therapy plans (6 plans including lymph node irradiation) and less than 90% in 3 photon plans (1 plan including lymph node irradiation) for either left, right or both CTVp. The nodal CTV (CTVn) V90% was less than 95% in 10 photon plans and less than 90% for 7 photon plans for at least one of the CTVn. The CTVp V95% and the CTVn V90% in the proton therapy plans were 97.8% or more. The median HI for CTVp was 0.10 (range, 0.07-0.95) using photons and 0.08 (range, 0.06–0.11) using protons (P < .001).

Median mean heart dose was 2.3 Gy (range, 0.7-12.4) for photon therapy plans versus 0.5 Gy RBE (range, 0.1-2.3) for proton therapy plans (P < .001), see Figure 2. Median V20Gy for both lungs was 18.9% (range, 5.7-30.4) using photons and 7.1% (range, 0.8-28.6) using protons (P < .001). Dosimetric results are provided in Table 3.

---

### Table 1. Summary of normal tissue complication models used in the present work.

| Endpoint                                      | Study design          | Population                      | Model type       | Model variables                                      | α/β ratio | Model references |
|-----------------------------------------------|-----------------------|---------------------------------|------------------|------------------------------------------------------|-----------|------------------|
| Early toxicities                              |                       |                                 |                  |                                                      |           |                  |
| Radiation dermatitis grade ≥2                 | Cohort series         | Breast cancer                   | Logistic         | EQD2 max to skin, radiation type                     | 10 [19]   | DeCesaris et al 2019 [19] |
| Radiation pneumonitis grade ≥1                | Pooled multi-center study | Thoracic cancers (mostly lung cancer) | Logistic         | Mean lung dose¹                                   | 4.0 [20] | Marks et al 2010 [21] |
| Acute esophagus toxicity grade ≥2             | Cohort series         | Non–small cell lung cancer      | Logistic         | Esophagus V35Gy                                    | NA        | Belderbos et al 2005 [22] |
| Late, non–life-threatening                    |                       |                                 |                  |                                                      |           |                  |
| Lung fibrosis grade ≥2                        | Cohort series         | Non–small cell lung cancer      | Lyman            | EUD for lungs                                       | 3.1 [23] | Tucker et al 2018 [24] |
| Breast fibrosis ≥ moderate                    | Pooled multi-center RCT study | Breast cancer                  | Logistic         | BEUD for breast                                    | 3 [25]   | Mukesh et al 2013 [25] |
| Hypothyroidy                                  | Cohort series         | Breast cancer                   | Logistic         | Thyroid gland volume receiving less than 20 Gy      | NA        | Huang et al 2021 [26] |
| Late, life-threatening                        |                       |                                 |                  |                                                      |           |                  |
| Coronary artery events at age 80              | Population-based case-control study | Breast cancer                  | Linear no-threshold | Mean heart dose,a age, cardiac risk factors | 2 [27]   | Darby et al 2013 [27] |
| Secondary lung cancer at age 80               | Nested case-control study | Breast cancer                  | Linear no-threshold | Mean lung dose, age, smoking status                 | NA        | Grantzau et al 2014 [28]b |
| Secondary esophageal cancer at age 80         | Nested case-control study | Breast cancer                  | Linear no-threshold | Mean esophagus dose, age                            | NA        | Joumy et al 2020 [29]c |

Abbreviations: NA, not applicable; EQD2, equivalent dose in 2 Gy fractions; EUD, equivalent uniform dose; BEUD, biologically effective uniform dose.

¹Biological equivalent, in 25 fractions, see text for details.

²General population lung cancer incidence rates for females in Denmark from NORDCAN [30], general population survival rates for females in Denmark from Statistics Denmark [31], rates of current and former smokers in Denmark from Danish Health Authority [32], percentage of smoking-related lung cancer deaths from Centers for Disease Control and Prevention (CDC) [33].

³General population esophageal cancer incidence rates for females in Denmark from NORDCAN [30], general population survival rates for females in Denmark from Statistics Denmark [31].

Late, life-threatening toxicities were modeled as excess absolute risk (EAR) of having an event before the age of 80 years. Secondary lung and esophageal cancers were modeled following the methodology in Brodin et al [34]. The EAR of secondary lung cancer for never-smokers was assumed to be 0% since Grantzau et al [28] found a non–statistically significant excess relative risk of 0.06 per Gy to the center of the lung tumor for never-smokers.

Coronary artery events were defined as myocardial infarction, coronary revascularization, death from ischemic or unstable angina [27]. The EAR of a coronary artery event was modeled twice for each patient: first assuming no preexisting cardiac risk factors and second assuming preexisting cardiac risk factors. Cardiac risk factors included current smoking, body mass index ≥ 30, and a history of ischemic heart disease, diabetes, or chronic obstructive pulmonary disease [27].
Table 2. Patient and treatment characteristics for the 24 patients included in the study.

| Parameter                              | Value, n (%)       |
|----------------------------------------|--------------------|
|                                        | Left side | Right side |
| Tumor histology                        |           |           |
| Invasive ductal carcinoma               | 15 (63)   | 16 (67)   |
| Invasive lobular carcinoma              | 6 (25)    | 5 (21)    |
| Ductal carcinoma in situ                | 3 (13)    | 3 (13)    |
| Tumor size                              |           |           |
| T1 (<20 mm)                            | 11 (46)   | 12 (50)   |
| T2 (20–50 mm)                          | 8 (33)    | 7 (29)    |
| T3 (>50 mm)                            | 2 (8)     | 2 (8)     |
| Not applicable*                         | 3 (13)    | 3 (13)    |
| Malignancy grade, ductal only           |           |           |
| I                                      | 4 (17)    | 4 (17)    |
| II                                     | 15 (63)   | 13 (54)   |
| III                                    | 2 (8)     | 3 (13)    |
| Not applicable*                         | 3 (13)    | 3 (13)    |
| Unknown                                | 0 (0)     | 1 (4)     |
| Number of positive LN                  |           |           |
| 0                                      | 9 (38)    | 15 (63)   |
| 1–3                                    | 9 (38)    | 6 (25)    |
| 4–9                                    | 2 (8)     | 0 (0)     |
| ≥10                                    | 1 (4)     | 0 (0)     |
| Not applicable*                         | 3 (13)    | 3 (13)    |
| HER2 status                            |           |           |
| Positive                               | 2 (8)     | 0 (0)     |
| Negative                               | 19 (79)   | 21 (88)   |
| Not applicable*                         | 3 (13)    | 3 (13)    |
| ER status                              |           |           |
| Positive                               | 19 (79)   | 20 (83)   |
| Negative                               | 2 (8)     | 1 (4)     |
| Not applicable*                         | 3 (13)    | 3 (13)    |
| Adjuvant chemotherapy                  |           |           |
| Epirubicin + Cyclophosphamide + Docetaxel | 8 (33) |
| Epirubicin + Cyclophosphamide + Paclitaxel | 3 (13) |
| None                                   | 12 (50)   |           |
| Unknown                                | 1 (4)     |           |
| Dose-fractionation scheme              |           |           |
| 40 Gy in 15 fractions                  | 11 (46)   |           |
| 50 Gy in 25 fractions                  | 9 (38)    |           |
| Combination                            | 4 (17)    |           |
| CTVp                                   |           |           |
| Bilateral chest wall                   | 4 (17)    |           |
| Bilateral whole breast                 | 16 (67)   |           |
| Chest wall & whole breast              | 4 (17)    |           |
| Lymph node irradiation                 |           |           |
| No LN irradiation                      | 12 (50)   |           |
| Left side only                         | 6 (25)    |           |
| Right side only                        | 1 (4)     |           |
| Both sides                             | 5 (21)    |           |
| Photon therapy planning technique      |           |           |
| 3D CRT                                 | 21 (88)   |           |
| VMAT                                   | 3 (13)    |           |
| Free breathing or DIBH                 |           |           |
| Free breathing                         | 12 (50)   |           |
| DIBH                                   | 12 (50)   |           |

Abbreviations: n, number of patients; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; CTVp, primary clinical target volume; LN, lymph node; CRT, conformal radiotherapy; VMAT, volumetric arc therapy; DIBH, deep inspiration breath-hold.

*aDuctal carcinoma in situ.*
Median NTCP of radiation dermatitis ≥ grade 2 was 18.3% (range, 5.4-41.7) with photon therapy and 58.4% (range, 31.4-69.7) with proton therapy. Median EAR of coronary event at age 80 assuming all patients having preexisting cardiac risk factors was 1.0% (range, 0.0-5.6) with photons and 0.2% (range, 0.0-1.3) with protons. Median EAR of secondary lung cancer at age 80 for current and former smokers was 4.8% (range, 0.0-17.0) using photons and 2.7% (range, 0.0-13.6) using protons. Risk estimates for all the studied radiation-induced toxicities for the delivered photon therapy plans and the competing proton therapy plans are provided in Table B1 and in Figure B1 in Supplemental Appendix B. Figure 3 shows a box plot of difference in NTCP between photon and proton therapy for the studied endpoints.

Discussion

For patients with bilateral breast cancer, we observed compromises on CTVp coverage (V95% < 95%) for half the patients with the delivered photon plans (all treated with 3D CRT), often to avoid extensive dose to the heart or to avoid overlap between the tangential fields. Adequate target coverage could probably have been obtained using the VMAT technique, but might, in return, increase the dose to the heart and lungs.

It is difficult to weigh the importance of different early and late toxicity risks. However, studies looking at one endpoint at a time may inadvertently bias toward one of the modalities. In this study, we observed a reduced risk of coronary artery events and lung endpoints but a greater risk of radiation dermatitis and larger exposure of the esophagus with the proton therapy plans compared with the photon therapy plans.

The DBCG-IMN study found that IMN irradiation improved overall survival in patients with high-risk unilateral breast cancer [35] and the NCIC-CTG MA.20 and EORTC 22922/10925 randomized controlled trials showed that regional lymph node irradiation reduced the rate of breast cancer recurrence [36–38]. Accordingly, a subgroup of our patients for whom large compromises on target coverage were made may have a clinically relevant benefit from adequate target coverage obtained with proton therapy. It should be noted that tumor control and survival data in synchronous bilateral breast cancer are limited [39].

In the DBCG Proton trial (ClinicalTrials.gov number, NCT04291378) [40], breast cancer patients are randomized between photon radiation therapy and proton therapy. Full target coverage is a prerequisite and patients may be included if exposure to
the heart or lungs exceeds a prespecified threshold with photon therapy [41]. After randomization, the optimal proton and photon plans are made (including possible target compromises as deemed optimal by treating physician). We suspect that most patients in the present study would have been candidates for the trial if treated today, especially patients referred for lymph node irradiation including the IMN. The Dutch proton therapy strategy is a model-based selection [42, 43] using delta NTCP \( \leq 2\% \) of coronary artery event at age 80 [27] as plan selection criteria. In this study, 2 patients had an estimated delta NTCP \( \leq 2\% \) assuming no cardiac risk factors, and 4 patients, assuming at least 1 risk factor. However, as illustrated by our analyses, comprehensive assessment of both target compromises and several competing endpoints are relevant for such selection processes.

The clinically delivered photon therapy plans were created in our department between 2013 and 2016; thus, recent improvements in photon therapy planning, such as knowledge-based treatment planning [44] or tangential VMAT planning [45], might allow for improved dose distributions. All patients receiving breast only irradiation were treated in free breathing,

### Table 3. Dosimetric results for the clinically delivered photon therapy plan and the competing proton therapy plan. Dose metrics in this table were reported assuming RBE = 1.1, and the metrics were not fractionation corrected. Esophagus and thyroid gland were only delineated and evaluated in patients receiving local regional irradiation (12 patients). Note that patients receiving breast only irradiation were treated in free breathing, and patients receiving local regional irradiation were treated in deep inspiration breath-hold. Abbreviations: CTVp, primary clinical target volume; LN, lymph nodes; IMN, internal mammary nodes; HI, homogeneity index; VXX%, volume that received at least XX% of the prescribed dose; VXXGy, volume that received at least XX Gy; CV20Gy, volume that received less than 20 Gy.

|                      | No LN irradiation (12 patients) | LN irradiation (12 patients) |
|----------------------|---------------------------------|------------------------------|
|                      | Photon, median (range)          | Proton, median (range)       | Photon, median (range) | Proton, median (range) |
| CTVp                 |                                 |                              |                            |                            |
| Left CTVp V95%, %    | 96.4 (83.5–99.2)                | 99.5 (98.0–100)              | 98.2 (91.3–100)          | 98.9 (97.8–99.9)          |
| Right CTVp V95%, %   | 98.0 (90.2–99.2)                | 99.4 (98.3–100)              | 95.7 (87.5–100)          | 99.1 (98.0–99.9)          |
| HI CTVp              | 0.09 (0.07–0.95)                | 0.08 (0.06–0.09)             | 0.12 (0.07–0.89)         | 0.09 (0.07–0.11)          |
| LN, %                |                                 |                              |                            |                            |
| Left LN V90%         | –                               | –                            | 97.0 (87.9–100)          | 99.7 (99.1–100)          |
| Right LN V90%        | –                               | –                            | 91.0 (81.4–99.8)         | 99.8 (99.3–100)          |
| IMN, %               |                                 |                              |                            |                            |
| Left IMN V90%        | –                               | –                            | 82.2 (0.7–100)           | 99.9 (98.6–100)          |
| Right IMN V90%       | –                               | –                            | 15.3 (0.6–98.2)          | 100 (98.3–100)           |
| Heart                |                                 |                              |                            |                            |
| Mean dose, Gy        | 2.1 (0.7–11.9)                  | 0.3 (0.1–0.5)                | 2.4 (1.2–12.4)           | 1.3 (0.5–2.3)            |
| V20Gy, %             | 1.7 (0.0–5.5)                   | 0.0 (0.0–0.3)                | 0.5 (0.0–7.7)            | 1.1 (0.0–2.2)            |
| Lungs                |                                 |                              |                            |                            |
| Mean dose, Gy        | 5.9 (3.6–10.5)                  | 2.8 (2.0–4.2)                | 12.0 (8.3–16.2)          | 9.0 (5.7–12.5)           |
| V20Gy, %             | 10.2 (5.7–20.1)                 | 2.2 (0.8–6.3)                | 23.3 (16.3–30.4)         | 16.5 (7.8–28.6)          |
| Left lung             |                                 |                              |                            |                            |
| Mean dose, Gy        | 5.9 (3.2–9.8)                   | 2.7 (1.2–4.0)                | 14.8 (6.2–17.7)          | 10.1 (3.9–14.4)          |
| V20Gy, %             | 10.3 (5.5–20.6)                 | 2.1 (0.1–6.4)                | 26.8 (13.1–36.5)         | 20.6 (5.3–30.8)          |
| Right lung            |                                 |                              |                            |                            |
| Mean dose, Gy        | 6.5 (3.4–11.0)                  | 2.8 (2.0–4.3)                | 10.5 (5.6–16.3)          | 8.9 (4.0–12.2)           |
| V20Gy, %             | 11.3 (5.1–24.5)                 | 2.5 (1.1–6.3)                | 20.2 (8.8–34.1)          | 16.3 (3.0–26.7)          |
| Esophagus            |                                 |                              |                            |                            |
| Mean dose, Gy        | –                               | –                            | 3.5 (0.8–13.8)           | 4.1 (2.3–10.0)           |
| Maximum dose, Gy     | –                               | –                            | 36.1 (2.9–43.6)          | 43.2 (25.9–49.3)         |
| V35Gy, %             | –                               | –                            | 0.05 (0.0–3.5)           | 1.6 (0.0–7.1)            |
| Thyroid gland        |                                 |                              |                            |                            |
| Mean dose, Gy        | –                               | –                            | 20.6 (2.9–42.1)          | 22.3 (2.8–49.3)          |
| Maximum dose, Gy     | –                               | –                            | 50.6 (33.4–52.8)         | 51.3 (29.8–52.6)         |
| CV20Gy, cm³           | –                               | –                            | 5.7 (1.2–14.7)           | 4.2 (0.0–15.6)           |
| Skin, %              |                                 |                              |                            |                            |
| Maximum dose         | 104.8 (100.9–106.7)             | 103.0 (99.9–106.7)           | 108.0 (98.6–119.3)       | 102.6 (100.3–107.3)      |
| Body, cm³            |                                 |                              |                            |                            |
| V107%                | 0.0 (0.0–9.6)                   | 0.1 (0.0–4.4)                | 15.3 (1.1–42.5)          | 0.1 (0.0–0.8)            |
and treatment in DIBH could potentially have reduced the dose to the heart and lungs [46], and an expansion of the chest might have allowed for wider tangential angles. Proton therapy plans for breast cancer have been shown to be robust against respiratory motion when using an en face field arrangement [47, 48], and treatment planning studies have indicated no benefit from DIBH in proton therapy [5, 6] despite the caudal displacement of the heart in DIBH, moving it away from the IMN. This study presents a variety of modeled radiation-induced risks, all of which come with substantial uncertainties that should be acknowledged. The models for radiation pneumonitis, acute esophageal toxicity, and lung fibrosis are based on predominantly non–small cell lung cancer patients; it should be acknowledged that patients in this group are frailer, more often have comorbidities, and receive other dose distributions, concurrent chemotherapy, and fractionation schemes. Coronary artery events were modeled using dose-response data from a population-based case-control study [27] in which none of the patients received taxanes or trastuzumab and only a few were treated with anthracyclines; these treatments are known to affect the heart [49]. All the models, except for the radiation dermatitis model, are based on photon therapy data having different dose distributions and different biological effects than protons. For this study, the CTVp was cropped 5 mm from the body outline for all chest wall targets, which might have resulted in an overestimation of the maximum dose to skin (and therefore, an overestimation of the risk of radiation dermatitis) in photon therapy plans. The risks of telangiectasia, cosmesis, and brachial plexopathy were considered for the risk assessment; however, the risks were considered negligible as they depend on a dose above 108% to 110% of the prescription dose, which is restricted in DBCG guidelines [50]. We did not manage to establish models for rib fracture [51], oedema, arm, or shoulder morbidity.

A comprehensive toxicity risk assessment, using data-driven risk estimates, was conducted for 24 patients with synchronous bilateral breast cancer. Compromises in target coverage were seen in the clinical 3D CRT plans, whereas proton therapy plans could have provided sufficient target coverage, especially patients referred for lymph node irradiation including the IMN. Proton therapy led to the lowest estimated risk of radiation pneumonitis, lung and breast fibrosis, coronary artery events, and secondary lung cancer; however, it also led to a substantially higher risk of radiation dermatitis.

**ADDITIONAL INFORMATION AND DECLARATIONS**

The authors wish to thank Neige Journy for providing modeling details related to esophageal cancer risk.

**CrediT:** Line Bjerregaard Stick: conceptualization, methodology, data curation, formal analysis and writing – original draft; Maria Fuglsang Jensen: methodology and writing – review and editing; Søren M. Bentzen: methodology and writing – review and editing; Claus Kamby: writing – review and editing; Anni Young Lundgaard: data curation and writing – review and editing; Maja Vestmø Maraldo: data curation and writing – review and editing; Birgitte Vrou Offersen: writing – review and editing; Jen Yu: methodology and writing – review and editing; Ivan Richter Vogelius: conceptualization, methodology, writing – review and editing.

Stick et al (2021), *Int J Particle Ther*
Conflicts of interest: Line Bjerregaard Stick, PhD, is the recipient of a grant from Varian Medical Systems (Palo Alto, CA, USA). Ivan Richter Vogelius, PhD, DMSc, receives grants and educational fees from Varian Medical Systems and grants from ViewRay (Cleveland, OH, USA) and Brainlab (Munich, Germany).

Funding: Søren M. Bentzen, PhD, DMSc, was supported by funds through the Maryland Department of Health’s Cigarette Restitution Fund Program. The study is supported by Eva & Henry Frænkels Mindefond, Dagmar Marshalls Fond, Kirsten & Freddy Johansen’s award, and National Institutes of Health (NIH) grant No. P30 CA 134274-04.

Ethical approval: All patient data have been collected under internal review board (IRB) approved protocol.
11. Kheirelseid EAH, Jumustafa H, Miller N, Curran C, Sweeney K, Malone C, McLaughlin R, Newell J, Kerin MJ. Bilateral breast cancer: analysis of incidence, outcome, survival and disease characteristics. *Breast Cancer Res Treat*. 2011;126:131–40.

12. Jobsen JJ, van der Palen J, Ong F, Riemersma S, Struikmans H. Bilateral breast cancer, synchronous and metachronous; differences and outcome. *Breast Cancer Res Treat*. 2015;153:277–83.

13. Wang Y, Park JL. Radiation therapy of synchronous bilateral breast carcinoma (SBBC) using volumetric modulated arc therapy (VMAT). *Int J Radiat Oncol*. 2015;93:E554–5.

14. Damkjær SMS, Aznar MC, Pedersen AN, Vogelius IR, Bangsgaard JP, Josipovic M. Reduced lung dose and improved inspiration level reproducibility in visually guided DIBH compared to audio coached EIG radiotherapy for breast cancer patients. *Acta Oncol*. 2013;52:1458–63.

15. Nielsen MH, Berg M, Pedersen AN, Andersen K, Glavivcic V, Jakobsen EH, Jensen I, Josipovic M, Lorenzen EL, Nielsen HM, Stenbygaard L, Thomsen MS, Vallentin S, Zimmermann S, Offersen B V. Delineation of target volumes and organs at risk in adjuvant radiotherapy of early breast cancer: national guidelines and contouring atlas by the Danish Breast Cancer Cooperative Group. *Acta Oncol*. 2013;52:703–10.

16. Offersen B V., Boersma LJ, Kirkove C, Hol S, Aznar MC, Biete Sola A, Kirova YM, Pignol JP, Remouchamps V, Verhoeven K, Weltens C, Arenas M, Gabrys D, Kopec N, Krause M, Lundstedt D, Marinko T, Montero A, Yarnold J, Poortmans P. ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer. *Radiother Oncol*. 2015;114:3–10.

17. Feng M, Moran JM, Koelling T, Chughtai A, Chan JL, Freedman L, Hayman JA, Jagsi R, Jolly S, Larouere J, Sioriano J, Marsh R, Pierce LJ. Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer. *Int J Radiat Oncol*. 2011;79:10–8.

18. International Commission on Radiation Units and Measurements (ICRU). Report 83: prescribing, recording, and reporting photon-beam intensity-modulated radiation therapy (IMRT). *J ICRU*. 2010;10:27–40.

19. DeCesaris CM, Rice SR, Bentzen SM, Jatczak J, Mishra MV, Nichols EM. Quantification of acute skin toxicities in patients with breast cancer undergoing adjuvant proton versus photon radiation therapy: a single institutional experience. *Int J Radiat Oncol Biol Phys*. 2019;104:1084–90.

20. Bentzen SM, Dische S. Morbidity related to axillary irradiation in the treatment of breast cancer. *Acta Oncol*. 2000;39:337–47.

21. Marks LB, Bentzen SM, Deasy JO, Kong F-M (Spring) Bradley JD, Vogelius IS, El Naqa I, Hubbs JL, Lebesque JV, Timmerman RD, Martel MK, Jackson A. Radiation dose–volume effects in the lung. *Int J Radiat Oncol*. 2010;76:S70–6.

22. Belderbos J, Heemsbergen W, Hoogeman M, Pengel K, Rossi M, Lebesque J. Acute esophageal toxicity in non-small cell lung cancer patients after high dose conformal radiotherapy. *Radiother Oncol*. 2005;75:157–64.

23. Joiner MC, van der Kogel A. *Basic Clinical Radiobiology*. 4th ed. Boca Raton, FL: CRC Press; 2009.

24. Tucker SL, Xu T, Paganetti H, Deist T, Verma V, Choi N, Mohan R, Liao Z. Validation of effective dose as a better predictor of radiation pneumonitis risk than mean lung dose: secondary analysis of a randomized trial. *Int J Radiat Oncol Biol Phys*. 2019;103:403–10.

25. Mukesh MB, Harris E, Collette S, Coles CE, Bartelink H, Wilkinson J, Evans PM, Graham P, Haviland J, Poortmans P, Yarnold J, Jena R. Normal tissue complication probability (NTCP) parameters for breast fibrosis: pooled results from two randomised trials. *Radiother Oncol*. 2013;108:293–8.

26. Huang H, Roberson J, Hou W, Mani K, Valentine E, Ryu S, Stessin A. NTCP model for hypothyroidism after supraclavicular-directed radiation therapy for breast cancer. *Radiother Oncol*. 2021;154:87–92.

27. Darby SC, Ewertz M, Bennet AM, Blom-Goldman U, Brønnum D, Correa C, Cutter D, Gagliardi G, Gigante B, Jensen MB, Nisbet A, Peto R, Rahimi K, Taylor C, Hall P. Risk of ischemic heart disease in women after radiotherapy for breast cancer. *N Engl J Med*. 2013;368:987–98.

28. Grantzau T, Thomsen MS, Væth M, Overgaard J. Risk of second primary lung cancer in women after radiotherapy for breast cancer. *Radiother Oncol*. 2014;111:366–73.

29. Journy N, Schonfeld SJ, Hauptmann M, Roberti S, Howell RM, Smith SA, Vaalavirta L, Stovall M, van Leeuwen FE, Weathers RE, Hodgson D, Gilbert ES, Berrington de Gonzalez A, Morton LM. Dose-volume effects of breast cancer radiation therapy on the risk of second oesophageal cancer. *Radiother Oncol*. 2020;151:33–9.
30. NORDCAN. Cancer incidence per 100,000 by age for females in Denmark 2016. Accessed May 18, 2021. https://www-dep.iarc.fr/nordcan/English/frame.asp

31. Statistics Denmark. Survivors per 100,000 by age for females in Denmark from 2015 to 2019. Accessed May 18, 2021. https://www.statistikbanken.dk/

32. Danish Health Authority. Smoking habits in Denmark 2018. Accessed May 18, 2021. https://www.sst.dk/da/udgivelser/2019/danskernes-rygevaner-2018

33. Centers for Disease Control and Prevention (CDC). What are the risk factors for lung cancer? Accessed May 18, 2021. https://www.cdc.gov/cancer/lung/basic_info/risk_factors.htm

34. Brodin NP, Vogelius IR, Maraldo M V., Munck Af Rosenschöld P, Aznar MC, Kiil-Berthelsen A, Nilsson P, Björk-Eriksson T, Specht L, Bentzen SM. Life years lost-comparing potentially fatal late complications after radiotherapy for pediatric medulloblastoma on a common scale. Cancer. 2012;118:5432–40.

35. Thorsen LBJ, Offersen BV, Dane H, Berg M, Jensen I, Pedersen AN, Zimmermann SJ, Brodersen HJ, Overgaard M, Overgaard J. DBCG-IMN: A population-based cohort study on the effect of internal mammary node irradiation in early node-positive breast cancer. J Clin Oncol. 2016;34:314–20.

36. Whelan TJ, Olivotto IA, Parulekar WR, Ackerman I, Chua BH, Nabi A, Vallis KA, White JR, Rousseau P, Fortin A, Pierce LJ, Manchul L, Chafe S, Nolan MC, Craighead P, Bowen J, McCready DR, Pritchard KI, Gelmon K, Murray Y, Chapman JAW, Chen BE, Levine MN. Regional nodal irradiation in early-stage breast cancer. N Engl J Med. 2015;373:307–16.

37. Poortmans PM, Collette S, Kirkove C, Van Limbergen E, Budach V, Struikmans H, Collette L, Fourquet A, Maingon P, Valli M, De Winter K, Marnitz S, Barillot I, Scandolaro L, Vonk E, Rodenhuis C, Marsiglia H, Weidner N, Van Tienhoven G, Glanzmann C, Kuten A, Amigadra R, Bartelink H, Van Den Bogaert W. Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med. 2015;373:317–37.

38. Poortmans PM, Weltens C, Fortpied C, Kirkove C, Peignaux-Casasnovas K, Budach V, van der Leij F, Vonk E, Weidner N, Rivera S, van Tienhoven G, Fourquet A, Noel G, Veli M, Guckenberger M, Koller E, Racadot S, Abdah-Bortnyak R, Van Limbergen EF, Koiter E, Racadot S, Abdah-Bortnyak R, Van Limbergen EF, Engelen A, De Brouwer P, Struikmans H, Bartelink H. Internal mammary and medial supraclavicular lymph node chain irradiation in stage I–III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial. Lancet Oncol. 2020;21:1602–10.

39. Mejdahl MK, Wohlfahrt J, Holm M, Balslev E, Knoop AS, Tjønneland A, Melbye M, Kroman N. Breast cancer mortality in synchronous bilateral breast cancer patients. Br J Cancer. 2019;120:761–7.

40. Danish Breast Cancer Group (DBCG). The DBCG PROTON Trial. Adjuvant breast proton radiation therapy for early breast cancer patients: The Skagen Trial II, a clinically controlled randomised phase III trial. Accessed May 18, 2021. https://www.dbcg.dk/images/PDF/Protokoller/Proton/DBCG Proton trial hovedprotokol_version 1.1 220220_VEK godkendt.pdf

41. Stick LB, Lorenzen EL, Yates ES, Anandadas C, Andersen K, Aristei C, Byrne O, Hol S, Jensen I, Kirby AM, Kirova YM, Marrazzo L, Matias-Pérez A, Nielsen MMB, Nissen HD, Oliveros S, Verhoeven K, Vikström J, Offersen BV. Selection criteria for early breast cancer patients in the DBCG proton trial – The Randomised Phase III trial strategy. Clin Transl Radiat Oncol. 2021;27:126–31.

42. Langendijk JA, Boersma LJ, Rasch CRN, van Vulpmen M, Reitsma JB, van der Schaaf A, Schuit E. Clinical trial strategies to compare protons with photons. Semin Radiat Oncol. 2018;28:79–87.

43. Langendijk JA, Lambin P, De Ruysscher D, Widder J, Bos M, Verheij M. Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model-based approach. Radiother Oncol. 2013;107:267–73.

44. Poortmans PMP, Takanen S, Marta GN, Meattini I, Kaidar-Person O. Winter is over: the use of artificial intelligence to individualise radiation therapy for breast cancer. Breast. 2020;49:194–200.

45. Virén T, Heikkilä J, Myllyoja K, Koskela K, Lahtinen T, Seppälä J. Tangential volumetric modulated arc therapy technique for left-sided breast cancer radiotherapy. Radiat Oncol. 2015;10:1–8.

46. Nissen HD, Appelt AL. Improved heart, lung and target dose with deep inspiration breath hold in a large clinical series of breast cancer patients. Radiother Oncol. 2013;106:28–32.

47. Klaassen L, Petoukhova AL, Habraken SJM, Jacobs J, Sattler MGA, Verhoeven K, Klaver YLB. Effect of breathing motion on robustness of proton therapy plans for left-sided breast cancer patients with indication for locoregional irradiation. Acta Oncol. 2020;60:1–7.
48. Flejmer AM, Chehrazi B, Josefsson D, Toma-Dasu I, Dasu A. Impact of physiological breathing motion for breast cancer radiotherapy with proton beam scanning – an in silico study. Phys Medica. 2017;39:88–94.

49. Yeh ETH, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53:2231–2247.

50. Barnett GC, Wilkinson JS, Moody AM, Wilson CB, Twyman N, Wishart GC, Burnet NG, Coles CE. The cambridge breast intensity-modulated radiotherapy trial: Patient- and treatment-related factors that influence late toxicity. Clin Oncol. 2011; 23:662–73.

51. Wang CC, McNamara AL, Shin J, Schuermann J, Grassberger C, Taghian AG, Jimenez RB, MacDonald SM, Paganetti H. End-of-range radiobiological effect on rib fractures in patients receiving proton therapy for breast cancer. Int J Radiat Oncol Biol Phys. 2020;107:449–54.